Skip to main
INSP

INSP Stock Forecast & Price Target

INSP Analyst Ratings

Based on 17 analyst ratings
Hold
Strong Buy 12%
Buy 29%
Hold 59%
Sell 0%
Strong Sell 0%

Bulls say

Inspire Medical Systems is facing short-term challenges in regards to reimbursement and market uncertainty, leading to a downward revision in their revenue guidance for 2026. However, management has expressed confidence in their ability to return to revenue growth in 2027. The company's strong cash position, healthy gross margin, and expected profitability in the near term provide a solid foundation for the stock, but potential for multiple expansion is limited until there is greater visibility on future revenue growth.

Bears say

Inspire Medical Systems is facing significant headwinds in the near-term, with a recently announced reimbursement/coding disruption expected to impact revenues and profits. This, combined with long-term concerns about GLP-1 drugs and potential competition in the neurostimulation market, contribute to our negative outlook on the stock. While the recent launch of the Inspire V device is a positive development, the company's lowered guidance for FY2026 and challenging Q2 outlook make it difficult for us to remain optimistic about the stock's near-term prospects. As a result, we have downgraded our rating to Neutral and lowered our price target to $55, reflecting about 1x our FY27 revenue estimate.

INSP has been analyzed by 17 analysts, with a consensus rating of Hold. 12% of analysts recommend a Strong Buy, 29% recommend Buy, 59% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Inspire Medical Systems Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Inspire Medical Systems Inc (INSP) Forecast

Analysts have given INSP a Hold based on their latest research and market trends.

According to 17 analysts, INSP has a Hold consensus rating as of Jun 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $92.41, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $92.41, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Inspire Medical Systems Inc (INSP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.